EMA approval decision for obicetrapib and obicetrapib/ezetimibe fixed dose combo expected in 2H26 ---- Phase 3 PREVAIL CVOT overall event rate ...
Idorsia receives approval from Health Canada for JERAYGO (aprocitentan) as the first and only endothelin receptor antagonist (ERA) for the treatment of resistant hypertension.JERAYGO is a new oral ant ...
Idorsia receives approval from Health Canada for JERAYGOâ„¢ (aprocitentan) as the first and only endothelin receptor antagonist ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback